
Stanley S Ostrow MD
Assistant Professor of Medicine, SUNY Stony Brook
Join to View Full Profile
235 N Belle Mead RdEast Setauket, NY 11733
Phone+1 631-751-3000
Fax+1 631-751-3366
Dr. Ostrow is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
One Brooklyn Health System/Interfaith Medical CenterResidency, Internal Medicine, 1975 - 1976
New York Medical College at St Vincent's Hospital and Medical Center of New YorkInternship, Internal Medicine, 1974 - 1975
State University of New York Downstate Medical Center College of MedicineClass of 1974
Certifications & Licensure
NY State Medical License 1976 - 2026
FL State Medical License 1979 - 1981
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification OncoEMR by Flatiron Health, Flatiron Health, Inc., 2011, 2013-2016
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc, 2011, 2013-2016
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc, 2011, 2013-2016
Publications & Presentations
PubMed
- 31 citationsPhase I chemotherapy study of biochemical modulation of folinic acid and fluorouracil by gemcitabine in patients with solid tumor malignancies.Stefan Madajewicz, Patricia Hentschel, P. Burns, R. Caruso, John J. Fiore
Journal of Clinical Oncology. 2000-10-20 - 31 citationsDoxorubicin, cyclophosphamide, and whole body hyperthermia for treatment of advanced soft tissue sarcoma.Henry Gerad, David A. Van Echo, Whitacre My, Michael Ashman, Martin Helrich
Cancer. 1984-06-15 - 21 citationsRandomized study of cyclophosphamide, doxorubicin, and etoposide (VP16-213) with or without cisplatinum in non-small cell lung cancer.Joachim Z. Fuks, Joseph Aisner, D. A. Van Echo, H Schipper, Levitt M
Journal of Clinical Oncology. 1983-05-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









